Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: A comparison with 15O-labeled water-measured blood flow

Journal of Nuclear Medicine

Volumn 49, Issue 4, 2008, Pages 517-523

  Mullani, Nizar A ^a,c   Herbst, Roy S ^b   O'Neil, Roger G ^a   Gould, K Lance ^a   Barron, Bruce J ^a   Abbruzzese, James L ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NONE   (United States)

Author keywords

15O; 18F Fdg; Blood flow; Molecular imaging; Perfusion; PET; Tumor

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOSTATIN; FLUORODEOXYGLUCOSE F 18; OXYGEN 15; WATER;

ARTICLE; BACK MUSCLE; BLOOD FLOW; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG UPTAKE; FIRST PASS EFFECT; GLUCOSE METABOLISM; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REGRESSION ANALYSIS; TUMOR BLOOD FLOW; TUMOR DIAGNOSIS;

FLUORODEOXYGLUCOSE F18; HUMANS; MALE; OXYGEN RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; REGIONAL BLOOD FLOW;

EID: 42049121200     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.048504     Document Type: Article

References (37)

1. Bogler O, Mikkelsen T. Angiogenesis in glioma: molecular mechanisms and roadblocks to translation. Cancer J. 2003;9:205-213.
2. Neufeld G, Kessler O. Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer Metastasis Rev. 2006;25:373-385.
3. Merida I, Avila-Flores A. Tumor metabolism: new opportunities for cancer therapy. Clin Transl Oncol. 2006;8:711-716.
4. Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol. 2000;27:683-687.
5. Herbst RS. Therapeutic options to target angiogenesis in human malignancies. Expert Opin Emerg Drugs. 2006;11:635-650.
6. Johnson BF, Clay TM, Hobeika AC, Lyerly HK, Morse MA. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther. 2007;7:449-460.
7. 15O-labelled carbon dioxide or water, carbon monoxide and oxygen: a multicentre study in Japan. Eur J Nucl Med Mol Imaging. 2004;31:635-643.
8. 2 and CBF in a single PET scan with a dual tracer administration method. Phys Med Biol. 2007;52:1893-1908.
9. Mullani N, Herbst R, Abbruzzese J, et al First pass FDG measured blood flow in tumors: a comparison with O-15 labeled water measured blood flow [abstract]. Clin Positron Imaging. 2000;3(4):153.
10. Mullani NA, Ekas RD, Marani S, Kim EE, Gould KL. Feasibility of measuring first pass extraction and flow with rubidium-82 in the kidneys. Am J Physiol Imaging. 1990;5:133-140.
11. Mullani NA, Gould KL. First-pass measurements of regional blood flow with external detectors. J Nucl Med. 1983;24:577-581.
12. Mullani NA, Goldstein RA, Gould KL, et al. Myocardial perfusion with rubidium-82. I. Measurement of extraction fraction and flow with external detectors. J Nucl Med. 1983;24:898-906.
13. Yoshida K, Mullani N, Gould KL. Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med. 1996;37:1701-1712.
14. 18F-FDG kinetics. J Nucl Med. 2003;44:1933-1939.
15. 18F]FDG in skeletal muscle by PET: a four-compartment five-rate-constant model. Am J Physiol Endocrinol Metab. 2001;281:E524-E536.
16. Gould KL, Yoshida K, Hess MJ, Haynie M, Mullani N, Smalling RW. Myocardial metabolism of fluorodeoxyglucose compared to cell membrane integrity for the potassium analogue rubidium-82 for assessing infarct size in man by PET. J Nucl Med. 1991;32:1-9.
17. Eichling JO, Raichle ME, Grubb RL Jr, Larson KB, Ter-Pogossian MM. In vivo determination of cerebral blood volume with radioactive oxygen-15 in the monkey. Circ Res. 1975;37:707-714.
18. 15O-labeled water. Am J Physiol. 1976;230:543-552.
19. 15O. II: implementation and validation. J Nucl Med. 1983;24:790-798.
20. Mintun MA, Raichle ME, Martin WR, Herscovitch P. Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography. J Nucl Med. 1984;25:177-187.
21. Ruotsalainen U, Raitakari M, Nuutila P, et al. Quantitative blood flow measurement of skeletal muscle using oxygen-15-water and PET. J Nucl Med. 1997;38:314-319.
22. 15O-gas and water. J Cereb Blood Flow Metab. 2001;21:793-803.
23. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002;20:3804-3814.
24. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2002;20:3792-3803.
25. Nakagawa Y, Nakagawa K, Sdringola S, Mullani N, Gould KL. A precise, three-dimensional atlas of myocardial perfusion correlated with coronary arteriographic anatomy. J Nucl Cardiol. 2001;8:580-590.
26. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med. 2004;45:1829-1837.
27. Zasadny KR, Tatsumi M, Wahl RL. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging. 2003;30:274-280.
28. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst. 2005;97:172-187.
29. Li JL, Harris AL. Notch signaling from tumor cells: a new mechanism of angiogenesis. Cancer Cell. 2005;8:1-3.
30. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43:500-509.
31. Tateishi U, Nishihara H, Tsukamoto E, Morikawa T, Tamaki N, Miyasaka K. Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr. 2002;26:185-190.
32. Mullani NA, Herbst RS, Abbruzzese JL, et al. Non-linear response of blood flow and glucose metabolism in human tumors treated with antiangiogenic agent Endostatin [abstract]. J Nucl Med. 2001;42(suppl):P298.
33. Hirasawa S, Tsushima Y, Takei H, et al. Inverse correlation between tumor perfusion and glucose uptake in human head and neck tumors. Acad Radiol. 2007;14:312-318.
34. 18F-deoxyglucose. Nucl Med Commun. 2004;25:577-583.
35. Inaba T. Quantitative measurements of prostatic blood flow and blood volume by positron emission tomography. J Urol. 1992;148:1457-1460.
36. Buckley DL, Roberts C, Parker GJ, Logue JP, Hutchinson CE. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging - initial experience. Radiology. 2004;233:709-715.
37. Ives EP, Burke MA, Edmonds PR, Gomella LG, Halpern EJ. Quantitative computed tomography perfusion of prostate cancer: correlation with whole-mount pathology. Clin Prostate Cancer. 2005;4:109-112.